RESEARCH AND OPTION AGREEMENTResearch and Option Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • England and Wales
Net Sales shall mean, with respect to any Product, the gross amount invoiced with respect thereto (whether by the Buyer, any Affiliate of the Buyer, any co-marketer, collaborator, joint venturer or other partner with the Buyer or any of its Affiliates) in the Territory, less, to the extent deducted from or on such invoice consistent with GAAP, the following items:
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. 1ST AMENDMENT OF THE RESEARCH AND OPTION...Research and Option Agreement • April 25th, 2024 • CureVac N.V. • Pharmaceutical preparations
This 1st Amendment (“Amendment”) to the Research and Option Agreement (“Agreement”) is made and entered into effective as of 12 January 2023 (the “Effective Amendment Date”) by and between CureVac SE, Friedrich-Miescher-Str. 15, 72076 Tübingen, Germany, and myNEO NV, Ottergemsesteenweg Zuid 808 box 511, 9000 Ghent, Belgium.
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. AMENDMENT TO RESEARCH AND OPTION AGREEMENTResearch and Option Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to Research and Option Agreement (this “Amendment”) is made effective as of May 30, 2018 (the “First Amendment Effective Date”) between Virpax Pharmaceuticals, Inc. (“Virpax”) and MedPharm Limited (“MedPharm”). Virpax and MedPharm are each sometimes referred to herein as a “Party” and, collectively, as the “Parties.”
REDACTEDResearch and Option Agreement • April 25th, 2023 • CureVac N.V. • Pharmaceutical preparations
This Research and Option Agreement (this "Agreement") is made and entered into effective as of 12 May 2022 (the "Effective Date") by and between CureVac AG, Friedrich-Miescher-Str. 15, 72076 Tübingen, Germany ("CureVac"), and myNEO NV, Ottergemsesteenweg Zuid 808 box 511, 9000 Ghent, Belgium ("myNEO"). CureVac and myNEO are sometimes referred to herein individually as a "Party" and collectively as the "Parties."
RECITALSResearch and Option Agreement • August 14th, 1997 • Trega Biosciences Inc • Biological products, (no disgnostic substances) • California
AMENDED AND RESTATED RESEARCH AND OPTION AGREEMENT by and between GENENTECH, INC. and CURAGEN CORPORATION March 31, 2000Research and Option Agreement • March 26th, 2003 • Curagen Corp • Services-commercial physical & biological research • New York
Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
Confidential CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO RULE 24B-2 AND ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST. COPIES OF THIS EXHIBIT CONTAINING THE OMITTED INFORMATION HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND...Research and Option Agreement • June 16th, 2008 • Accelr8 Technology Corp • Laboratory analytical instruments • New Jersey
RESEARCH AND OPTION AGREEMENTResearch and Option Agreement • June 20th, 2024
WHEREAS: pursuant to the regulations of the Hebrew University of Jerusalem (“HUJ”), the rights and title to all inventions, know-how and research results of scientists of HUJ vest solely with Yissum; and
